Fig. 3
Kaplan–Meier estimate for factors affecting overall survival in BC-LMD patients. A TNBC-LMD patients had a significantly lower overall survival (2 months) when compared to HR + BC-LMD patients (5.3 months) and HER2 + BC-LMD patients (8.4 months). Median survival time between HR + and HER2 + BC-LMD patients did not significantly differ. B Patients receiving systemic therapy post BC-LMD diagnosis had a significantly higher median survival time (7.9 months) when compared to BC-LMD patients that did not receive systemic therapy (1.8 months). C Patients receiving intrathecal therapy post BC-LMD diagnosis had a significantly higher median survival time (11.8 months) when compared to BC-LMD patients that did not receive intrathecal therapy (1.9 months). D, E More specifically, overall survival median times were higher in patients that received intrathecal methotrexate (8.4 months) and/or intrathecal thiotepa (12 months) versus those that did not (2.9 months; 3.6 months, respectively). F patients receiving WBRT post BC-LMD diagnosis had a higher overall survival median time (6.5 months) than those who did not receive WBRT (2.7 months). HR + Hormone Receptor Positive; HER2 + Human Epidermal Growth Factor Receptor 2-Positive; TNBC Triple Negative Breast Cancer; LMD Leptomeningeal Disease; WBRT Whole Brain Radiation Therapy; IT Intrathecal; HR Hazard Ratio; CI Confidence Interval